drugset
drugset / Trial / NCT00927953

Treatment of West Nile Virus With MGAWN1

NCT00927953 ↗

Phase 2 Terminated 13 enrolled MacroGenics National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will test a drug called MGAWN1 for the treatment of West Nile infections.

Timeline

Start
2009-05
Primary completion
2011-02
Completion
2011-05

Outcome

Outcome not reported

Stopped (Enrollment): “Early termination due to the inability to enroll (13 of 120 subjects enrolled)”

Drugs

EvaluationDrugModalityDoseRoute
Subject MGAWN1 Monoclonal antibody 30 mg/kg Intravenous

Indications

West Nile fever central nervous system infectious disorder encephalitis meningitis